Batf3<sup>+</sup> DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy.

导出 LinkOut

翻译打印收藏纠错

作者： Jing,Liu ^[1] ; Elisa A,Rozeman ^[2] ; Jake S,O'Donnell ^[1] ; Stacey,Allen ^[3] ; Lorenzo,Fanchi ^[4] ; Mark J,Smyth ^[1] ; Christian U,Blank ^[2] ; Michele W L,Teng ^[3]

作者单位： Cancer Immunoregulation and Immunotherapy Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia. ^[1] Division of Molecular Oncology & Immunology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. ^[2] Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia. ^[3] School of Medicine, University of Queensland, Herston, Queensland, Australia. ^[4]

关键词 Batf3+ DC Neoadjuvant immunotherapy metastases mouse models surgery type I IFN

DOI 10.1080/2162402X.2018.1546068

PMID 30713806

发布时间 2021-01-12

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览7

Oncoimmunology

e1546068页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Batf3<sup>+</sup> DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy.

Oncoimmunology

相似文献

Oncoimmunology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Batf3<sup>+</sup> DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy.

Oncoimmunology

相似文献

Oncoimmunology

相关期刊

检索历史清除